Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04131634
Other study ID # 2019-1506
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 16, 2020
Est. completion date June 10, 2021

Study information

Verified date June 2021
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.


Description:

Oligo-progressive urothelial cancer with limited disease burden and progression on an anti-PD-1/L1 immune checkpoint inhibitor.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date June 10, 2021
Est. primary completion date December 17, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must be at least 18-years-old - ECOG performance status 0-2 - Patients must have pathology-proven metastatic urothelial carcinoma, with tissue sampling of at least the primary tumor. Tissue sampling of each presumed metastatic site is not necessary, provided that the patient already has a confirmed diagnosis of urothelial cancer. - Patients must be on immune checkpoint inhibitor therapy with radiographic scans to verify oligo-progression of at least one and = 6 sites of disease per RECIST 1.1. - Any of the currently FDA-approved PD-1/PD-L1 inhibitors are allowed. These include pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab. - At least 1 metastatic lesion must show stable disease, partial response or complete response per RECIST 1.1. - Patients must be able to understand and willing to sign written informed consent. - Patients must have acceptable tolerability of ongoing therapy as decided by the treating medical oncologist. - Patients must have a desire to continue ongoing therapy. - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. - A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: - Has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). - Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Exclusion Criteria: - Inability to receive further immune checkpoint inhibitor therapy - Anticipated survival of fewer than 12 weeks - Daily steroid requirement of > 10 mg prednisone or prednisone-equivalent. Steroid replacement therapy for adrenal insufficiency is permitted. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements. - Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Stereotactic Ablative Radiation
A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy

Locations

Country Name City State
United States Aurelie Garant Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) at 6 months Progression free survival (PFS) at 6 months in the patients for whom SAbR is added to the ICI after progression on ICI. PFS will be defined as the combination of progressive disease from SAbR start date and death from any cause. 6 months
Secondary The disease control rate The disease control rate in patients for whom SAbR is added to ICI after progression on ICI. DCR will be assessed per RECIST 1.1 criteria and defined as the combination of: Complete Response (CR), Partial Response (PR), or Stable Disease (SD). 6 months
Secondary The time to next-line systemic therapy The time to initiation of next-line systemic therapy following the addition of SAbR to ICI after progression on ICI. 6 months
Secondary Overall survival of patients The overall survival of patients since progression on ICI or at the study registration. Overall survival (OS) will be defined using the interval between enrollment and death from any cause. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Terminated NCT01663285 - Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) Phase 2
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Terminated NCT04629339 - Study of INCB086550 in Select Solid Tumors Phase 2
Recruiting NCT04114136 - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Terminated NCT04501094 - A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Phase 2
Recruiting NCT04923178 - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Completed NCT02256436 - A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Phase 3
Terminated NCT00995488 - Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer Phase 2
Completed NCT01206426 - Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
Active, not recruiting NCT03425201 - Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) Phase 1/Phase 2
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04180371 - Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Phase 1/Phase 2
Active, not recruiting NCT02891161 - Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Phase 1/Phase 2
Withdrawn NCT01700010 - Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer Phase 2
Active, not recruiting NCT02516241 - Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Phase 3
Active, not recruiting NCT04152018 - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Phase 1